Tesamorelin — Vendor Pricing & Purity Guide
Research Overview
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids — the full-length GHRH molecule with a trans-3-hexenoic acid modification at the N-terminus for improved stability. It is FDA-approved under the brand name Egrifta for reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients on antiretroviral therapy.
Tesamorelin works by stimulating the anterior pituitary to release growth hormone, which in turn increases hepatic IGF-1 production. Its specific FDA-approved indication for visceral adiposity reduction reflects GH's potent lipolytic (fat-burning) effects, particularly on visceral adipose tissue. Unlike exogenous GH, Tesamorelin preserves physiological GH pulsatility and does not suppress endogenous GH production.
Among GHRH analogs, Tesamorelin is unique in having full FDA approval and extensive Phase III clinical trial data. It represents the most potent and well-characterized GHRH analog available, though its higher cost reflects the full-length molecule's manufacturing complexity compared to shorter analogs like Sermorelin or CJC-1295.
Key Research Findings
- •FDA-approved (Egrifta) for reduction of excess visceral abdominal fat in HIV lipodystrophy
- •Reduced visceral adipose tissue by 15-18% over 26 weeks in Phase III LIPO-010 and LIPO-011 trials
- •Increased IGF-1 levels by 80-100% above baseline while maintaining physiological GH pulsatility
- •Improved lipid profiles including reduced triglycerides and improved LDL particle size in clinical trials
- •Demonstrated cognitive benefits in aging adults — improved verbal memory and executive function in Phase II trials
- •Research ongoing for NASH/fatty liver disease with promising Phase II results showing reduced liver fat
Research Dosage Protocols
Tesamorelin is FDA-approved at a dose of 2 mg administered subcutaneously once daily. The FDA label specifies abdominal injection with site rotation.
For research use, Tesamorelin is supplied as lyophilized powder requiring reconstitution with sterile water. The reconstituted solution should be refrigerated and used within 24-48 hours per manufacturer guidelines.
Research protocols for non-HIV indications (cognitive function, NASH) have used the same 2 mg daily dose. Clinical trials required baseline CT imaging to confirm visceral adiposity and monitored IGF-1 levels throughout treatment.
For research reference only. Not medical advice. Not for human consumption.
Price Comparison (21 products from 14 vendors)
| Vendor | Price | Stock |
|---|---|---|
| Peptide Crafters | $60.00 $6.00/mg 10mg lyophilized | In Stock |
| Polaris Peptides | $65.00 $6.50/mg 10mg lyophilized | In Stock |
| Triumphant Labs | $73.00 $7.30/mg 10mg | In Stock |
| Simple Peptide | $75.00 $7.50/mg 10mg lyophilized | In Stock |
| Biotech Peptides | $38.00 $7.60/mg 5mg vial | In Stock |
| Peptide Crafters | $85.00 $7.73/mg 11mg blend | In Stock |
| Paradigm Peptides | $80.00 $8.00/mg 10mg lyophilized | In Stock |
| Core Peptides | $43.00 $8.60/mg 5mg vial | In Stock |
| Soma Chems | $49.99 $10.00/mg 5mg vial | In Stock |
| Peptide Partners | $118.00 $11.80/mg 10mg | In Stock |
| Swiss Chems | $27.95 $13.97/mg 2mg vial | In Stock |
| BioLongevity Labs | $149.97 $15.00/mg 10mg vial | In Stock |
| Peptide Sciences | $75.00 $15.00/mg 5mg lyophilized | In Stock |
| Skye Peptides | $79.00 $15.80/mg 5mg lyophilized | In Stock |
| Pure Rawz | $18.34 $18.34/mg 1mg vial | In Stock |
| Skye Peptides | $69.00 $27.60/mg 2.5mg lyophilized | In Stock |
| Simple Peptide | $109.00 $54.50/mg 2mg lyophilized | In Stock |
| Triumphant Labs | $621.00 $62.10/mg 10mg | In Stock |
| Peptide Sciences | $300.00 $150.00/mg 2mg lyophilized | In Stock |
| Skye Peptides | $84.00 lyophilized | In Stock |
| Skye Peptides | $69.00 lyophilized | In Stock |
Frequently Asked Questions
What is Tesamorelin?
Tesamorelin is an FDA-approved GHRH analog that stimulates natural growth hormone production. It is the only GHRH-based drug with full FDA approval, indicated for reducing visceral abdominal fat in HIV patients.
How does Tesamorelin compare to Sermorelin and CJC-1295?
Tesamorelin is the full-length GHRH (44 amino acids) with enhanced stability. Sermorelin is the truncated first 29 amino acids. CJC-1295 is a modified 29-amino-acid analog with extended half-life. Tesamorelin has the most clinical data and the only FDA approval.
Does Tesamorelin reduce belly fat?
In FDA Phase III trials, Tesamorelin reduced visceral adipose tissue by 15-18% over 26 weeks. It specifically targets visceral (deep abdominal) fat through GH-mediated lipolysis. Effects reversed upon discontinuation.
Where can I buy Tesamorelin for research?
Tesamorelin is available from research peptide vendors. Compare pricing in the table above.